NCIt definition : A monoclonal antibody targeting the co-inhibitory receptor lymphocyte-activation gene
3 protein (LAG-3; LAG3; CD223), with potential immune checkpoint inhibitory and antineoplastic
activities. Upon administration, brivestobart targets and binds to LAG-3 expressed
by tumor infiltrating lymphocytes (TILs) and blocks the interaction between LAG-3
and major histocompatibility complex class II (MHC II) molecules on the surface of
antigen-presenting cells (APCs) and tumor cells. This prevents the negative regulation
of T-cell activity that occurs via LAG-3-MHC II binding and enhances a cytotoxic T-lymphocyte
(CTL)-mediated immune response against tumor cells, leading to a reduction in tumor
growth. LAG-3, a member of the immunoglobulin superfamily (IgSF), negatively regulates
both the proliferation and activation of T-cells. Its expression on TILs is associated
with tumor-mediated immune suppression.;
Semantic type(s)